Other serious events registered included a cardioembolic stroke due to atrial fibrillation in an 82-year-old patient treated with an aromatase inhibitor and a myocardial infarction in an 81-year-old patient, also treated with an aromatase inhibitor, who subsequently developed normotensive hydrocephalus. This evidence concerns the gene CYP19A1 and cardioembolic stroke.